Aerie in the News
April 4, 2013
Aerie
Pharmaceuticals Names Vicente Anido, Jr. as Chairman of the Board, and David
Epstein as Chairman of Aerie’s Scientific Advisory Board
Jan 3, 2013
Aerie
Pharmaceuticals to Present at 31st Annual J.P. Morgan Healthcare Conference
November 1, 2012
Aerie
Pharmaceuticals Announces Positive Phase 2a Clinical Results for its Novel,
Dual Mechanism Compound, AR-13324, for the Treatment of Glaucoma
October 30, 2012
Aerie
Pharmaceuticals Announces Positive Phase 2a Clinical Results for a Fixed
Combination of its Rho Kinase Inhibitor, AR-12286, with Travoprost for the
Treatment of Glaucoma
October 18, 2012
Aerie
Pharmaceuticals Appoints Richard J. Rubino as Chief Financial Officer
April 12, 2011
American
Journal of Ophthalmology - Ocular Hypotensive Effect of the Rho Kinase
Inhibitor AR-12286 in Patients With Glaucoma and Ocular Hypertension
March 7, 2011
Aerie Pharmaceuticals
Completes $30 Million Series B Financing to Fund Further Development of
Innovative Glaucoma Product Portfolio
October 26, 2009
Biocentury - RhoKing
Glaucoma
October 22, 2009
Aerie Pharmaceuticals’ ROCK Inhibitor,
AR-12286, Demonstrates Positive Results in Glaucoma Patients in a Phase 2a
Study
|
